

Gibson Dunn Represented Apogee Therapeutics on \$345 Million Offering of Common Stock and Pre-Funded Warrants

Firm News | October 10, 2025

Gibson Dunn represented Apogee Therapeutics, Inc., a clinical-stage biotechnology company, in a public offering of 8,048,782 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,097,561 shares. The offering also included the issuance to certain investors of pre-funded warrants to purchase up to 365,853 shares of common stock. The offering generated aggregate gross proceeds of approximately \$345 million to Apogee. Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen acted as joint book-running managers for the offering. BTIG acted as passive bookrunner for the offering. Our team included partners Ryan Murr, Branden Berns, and Melanie Neary and associates Candice Johnson, Jasmine Vitug, and Anika Gidwani.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Candice D. Johnson](#)

[Jasmine L. Vitug](#)

[Anika Gidwani](#)

Related Capabilities

[Life Sciences](#)

[Capital Markets](#)